Cell Biology Science Small Molecule 
Drug Discovery World
APRIL 5, 2023
Members contribute their expertise in high throughput screening, structural biology, medicinal chemistry, compound profiling, cancer cell biology, and in vivo and in vitro models for oncology.
Drug Target Review
JULY 13, 2023
The aim is to establish condensate biology as a fundamental branch of cell biology – “cell biology 2.0” The underlying biology and processes upon which the company was founded have broad applicability across various human disease areas. Klein notes the importance of Dewpoint’s disease-agnostic approach.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Target Review
AUGUST 10, 2023
This discovery sheds new light on the intricate mechanisms at play within cancer cells when faced with adverse conditions. When bound to GRP78, ID2 loses its inhibitory function, leading to increased invasiveness of cancer cells.
NIH Director's Blog: Drug Discovery
APRIL 11, 2017
Credit: National Center for Advancing Translational Sciences, NIH When you think of the causes of infectious diseases, what first comes to mind are probably viruses and bacteria. Missing was the usual pocket-shaped active site, where a traditional small molecule can readily bind and block function. ” [1] Or was it?
The Pharma Data
OCTOBER 19, 2020
At Aduro, he was responsible for all manufacturing and supply chain activities for the company’s biologics and small molecules and managed a transatlantic team. in Cell Biology from Utrecht University. UTRECHT, The Netherlands–( BUSINESS WIRE )– AM-Pharma B.V. , Kenilworth, N.J., Dr. van de Laar holds a M.Sc.
Drug Target Review
JULY 23, 2024
I sharpened my focus in my early teen age years when I decided I wanted to harness my interest in human biology to make medicines for people. I studied Natural Sciences at the University of Cambridge, where I was exposed to a range of disciplines from chemistry to physiology, specialising in my last year in biochemistry.
Drug Discovery World
NOVEMBER 13, 2023
Thereafter, the following presentations will take place: Melody Shahsavarian, PhD, Digital Biologics Platform, Large Molecules Research, Sanofi, on: ‘Enhancing antibody discovery with generative AI’. Hiroki Shirai, PhD, Coordinator, RIKEN Center for Computational Science, on: ‘Applying deep learning anomaly detection to antibody structures’.
Expert insights. Personalized for you.
130 
Let's personalize your content